China
· Delayed Price · Currency is CNY China Resources Double-Crane Pharmaceutical Co.,Ltd. Statistics
Total Valuation
China Resources Double-Crane Pharmaceutical Co.,Ltd. has a market cap or net worth of CNY 19.91 billion. The enterprise value is 18.61 billion.
| Market Cap | 19.91B |
| Enterprise Value | 18.61B |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | Nov 8, 2024 |
Share Statistics
China Resources Double-Crane Pharmaceutical Co.,Ltd. has 1.03 billion shares outstanding. The number of shares has decreased by -0.71% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 1.03B |
| Shares Change (YoY) | -0.71% |
| Shares Change (QoQ) | -0.06% |
| Owned by Insiders (%) | 0.12% |
| Owned by Institutions (%) | 11.95% |
| Float | 399.38M |
Valuation Ratios
The trailing PE ratio is 14.78 and the forward PE ratio is 11.33.
| PE Ratio | 14.78 |
| Forward PE | 11.33 |
| PS Ratio | 1.93 |
| PB Ratio | 1.96 |
| P/TBV Ratio | 2.72 |
| P/FCF Ratio | 18.40 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.51, with an EV/FCF ratio of 17.20.
| EV / Earnings | 13.81 |
| EV / Sales | 1.80 |
| EV / EBITDA | 8.51 |
| EV / EBIT | 12.49 |
| EV / FCF | 17.20 |
Financial Position
The company has a current ratio of 1.59, with a Debt / Equity ratio of 0.07.
| Current Ratio | 1.59 |
| Quick Ratio | 1.19 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.34 |
| Debt / FCF | 0.66 |
| Interest Coverage | 120.65 |
Financial Efficiency
Return on equity (ROE) is 12.07% and return on invested capital (ROIC) is 7.67%.
| Return on Equity (ROE) | 12.07% |
| Return on Assets (ROA) | 5.63% |
| Return on Capital (ROIC) | 7.67% |
| Revenue Per Employee | 841,305 |
| Profits Per Employee | 109,858 |
| Employee Count | 12,269 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 2.82 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +1.69% in the last 52 weeks. The beta is 0.14, so China Resources Double-Crane Pharmaceutical Co.,Ltd.'s price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +1.69% |
| 50-Day Moving Average | 20.99 |
| 200-Day Moving Average | 20.77 |
| Relative Strength Index (RSI) | 36.79 |
| Average Volume (20 Days) | 10,248,851 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, China Resources Double-Crane Pharmaceutical Co.,Ltd. had revenue of CNY 10.32 billion and earned 1.35 billion in profits. Earnings per share was 1.31.
| Revenue | 10.32B |
| Gross Profit | 5.79B |
| Operating Income | 1.42B |
| Pretax Income | 1.54B |
| Net Income | 1.35B |
| EBITDA | 2.10B |
| EBIT | 1.42B |
| Earnings Per Share (EPS) | 1.31 |
Balance Sheet
The company has 2.71 billion in cash and 711.52 million in debt, giving a net cash position of 1.99 billion or 1.94 per share.
| Cash & Cash Equivalents | 2.71B |
| Total Debt | 711.52M |
| Net Cash | 1.99B |
| Net Cash Per Share | 1.94 |
| Equity (Book Value) | 10.89B |
| Book Value Per Share | 9.89 |
| Working Capital | 2.72B |
Cash Flow
In the last 12 months, operating cash flow was 1.84 billion and capital expenditures -757.67 million, giving a free cash flow of 1.08 billion.
| Operating Cash Flow | 1.84B |
| Capital Expenditures | -757.67M |
| Free Cash Flow | 1.08B |
| FCF Per Share | 1.05 |
Margins
Gross margin is 56.06%, with operating and profit margins of 13.79% and 13.06%.
| Gross Margin | 56.06% |
| Operating Margin | 13.79% |
| Pretax Margin | 14.95% |
| Profit Margin | 13.06% |
| EBITDA Margin | 20.30% |
| EBIT Margin | 13.79% |
| FCF Margin | 10.48% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.03%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.03% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | 83.45% |
| Buyback Yield | 0.71% |
| Shareholder Yield | 1.74% |
| Earnings Yield | 6.76% |
| FCF Yield | 5.43% |
Stock Splits
The last stock split was on August 16, 2018. It was a forward split with a ratio of 1.2.
| Last Split Date | Aug 16, 2018 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
China Resources Double-Crane Pharmaceutical Co.,Ltd. has an Altman Z-Score of 3.98.
| Altman Z-Score | 3.98 |
| Piotroski F-Score | n/a |